Radiotherapy in the rituximab era: still a place?

M Pfreundschuh

doi:10.4081/hmr.v3i3.569

Abstracts

12 June 2009

Vol. 3 No. 3 (2009)

https://doi.org/10.4081/hmr.v3i3.569

Radiotherapy in the rituximab era: still a place?

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

PDF

272

Views

159

Downloads

Authors

M Pfreundschuh

support@pagepress.org

The RICOVER60 trial has shown that 6 cycles of CHOP-14 with 8 applications of rituximab (6xR-CHOP-14) was superior to 8xR-CHOP-14, 6xCHOP-14 and 8xCHOP-14 in elderly patients with CD20-positive aggressive lymphoma. In that trial 117/306 (36%) of the patients in the 6xRCHOP- 14 arm were assigned to receive additional radiotherapy (Rx) to bulky disease (Pfreundschuh et al., Lancet Oncol 2008). To study the relevance of additional Rx to bulky disease we subsequently initiated a prospective study in which no Rx was planned after 6 x R-CHOP-14.